Amgen, Cytokinetics Announce Disappointing Phase 2 Data For Heart Failure … – Medical Daily
Amgen, Cytokinetics Announce Disappointing Phase 2 Data For Heart Failure …Medical Daily(Amgen, Creative Commons) Co-developers Amgen and Cytokinetics announced disappointing results for omecamtiv mecarbil in a Phase 2 trial of the drug in patients w…
